No abstract available
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage*
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Biopsy, Needle
-
Fatal Outcome
-
Female
-
Follow-Up Studies
-
Humans
-
Immunohistochemistry
-
Lymphoma, T-Cell, Peripheral / drug therapy*
-
Lymphoma, T-Cell, Peripheral / pathology
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy*
-
Neoplasm Recurrence, Local / pathology
-
Remission Induction
-
Risk Assessment
-
Time Factors
-
Treatment Outcome
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab